A clinical-stage biotechnology company focused on developing therapies for diseases of the retina, particularly age-related macular degeneration and other ophthalmic conditions. Its pipeline has centered on drug candidates targeting vision loss through novel anti-angiogenic and complement pathway ap...
1 member of Congress has disclosed 1 trade in Ophthotech Pharmaceuticals Inc (OPHT), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-11-18 | MIKE KELLY | buy | $1K – $15K |